Xuejun Wen

Notable Publications:

Wen X, Shi C, Zeng X, Zhao L, Yao L, Liu Z, Feng L, Zhang D, Huang J, Li Y, Lin Q, Chen H, Zhuang R, Chen X, Zhang X, Guo Z. A paradigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect. Clin Cancer Res, 2022, 28(13):2923-2937.

Wen X, Wang R, Xu P, Shi M, Shang Q, Zeng X, Zeng X, Liu J, Wang X, Zhu Z, Guo Z, Chen X, Zhang J. Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03. Eur J Nucl Med Mol Imaging, 2024. doi:10.1007/s00259-024-06634-9.

Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X. Development of [177Lu]Lu‑LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging, 2023. doi:10.1007/s00259-023-06229-w.

Zhao L, Wen X, Xu W, Pang Y, Sun L, Wu X, Xu P, Zhang J, Guo Z, Lin Q, Chen X, Chen H. Clinical evaluation of [68Ga]Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin αvβ3 in various cancer types. J Nucl Med, 2023;64:1–8.

Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z, Zhang X, Khong P, Chen X. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics, 2022;12(1):422-433.

Wen X, Shi C, Yang L, Zeng X, Lin X, Huang J, Li Y, Zhuang R, Zhu H, Guo Z, Zhang X. A radioiodinated FR‑β‑targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. Eur J Nucl Med Mol Imaging, 2021. doi:10.1007/s00259-021-05447-4.

Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, Zeng X, Zhang J, Wu X, Zhang X, Miao W, Xu P, Guo Z, Zhang J, Chen X. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics, 2022;12(16):7180-7190.

Wen X, Zeng X, Liu J, Zeng X, Zhang Y, Cheng X, Huang J, Li Y, Zhuang R, Zhang X, Guo Z. In vivo comparative study of radioiodinated folate receptor targeting albumin probes for atherosclerosis plaque imaging. Bioconjugate Chem, 2023;34(12):2387-2397.

Wen X, Zeng X, Cheng X, Zeng X, Liu J, Zhang Y, Li Y, Chen H, Huang J, Guo Z, Chen X, Zhang X. PD-L1-targeted radionuclide therapy combined with αPD-L1 antibody immunotherapy synergistically improves the antitumor effect. Mol Pharmaceutics, 2022;19:3612−3622.

Wen X, Zeng X, Liu J, Zhang Y, Shi C, Wu X, Zhuang R, Chen X, Zhang X, Guo Z. Synergism of 64Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect. Bioconjugate Chem, 2022;33:2170−2179.

Wen X, Zeng X, Shi C, Liu J, Zhang Y, Shi M, Li J, Chen H, Zhuang R, Chen X, Zhang X, Guo Z. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Adv Therap, 2022:2200193.

Wen X, Shi C, Xu D, Zhang P, Li Z, Li J, Su X, Zhuang R, Liu T, Guo Z, Zhang X. Radioiodinated portable albumin binder as a versatile agent for in vivo imaging with single-photon emission computed tomography. Mol Pharmaceutics, 2019;16(2):816-824.

Wen X, Shi C, Zhao L, Yao L, Xu D, Lin X, Su X, Liu T, Zhuang R, Lin Q, Chen H, Guo Z, Zhang X. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. Nucl Med Biol, 2020;86-87:44-51.

Zang J, Lin R, Wen X, et al. A head-to-head comparison of [68Ga]Ga-LNC1007 and 2-[18F]FDG/[68Ga]Ga-FAPI-02 PET/CT in patients with various cancers. Clin Nucl Med, 2023;48:861–868.

Yao L, Wen X, Guo W, Fang J, Zhang X, Guo Z, Huang J, Li Y. Novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics. Mol Pharmaceutics, 2022;19(9):3178-3186.

Zhang Y, Wen X, Wang Y, Yang X, Chen Y, Zeng X, Li Y, Huang J, Guo Z, Zhang X. Longitudinal microSPECT imaging of systemic sclerosis model mice with [99mTc]Tc-HYNFA via folate receptor targeting. Mol Pharmaceutics, 2023;20:473−480.